A detailed history of Anson Funds Management LP transactions in Bio Atla, Inc. stock. As of the latest transaction made, Anson Funds Management LP holds 4,601,066 shares of BCAB stock, worth $2.12 Million. This represents 0.35% of its overall portfolio holdings.

Number of Shares
4,601,066
Holding current value
$2.12 Million
% of portfolio
0.35%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025

BUY
$0.59 - $2.37 $2.71 Million - $10.9 Million
4,601,066 New
4,601,066 $2.71 Million

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $16.7M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Anson Funds Management LP Portfolio

Follow Anson Funds Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Anson Funds Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Anson Funds Management LP with notifications on news.